Inhibitory effect of antidepressants on B16F10 melanoma tumor growth

Pharmacological Reports

Volumn 65, Issue 3, 2013, Pages 672-681

  Grygier, Beata ^a   Arteta, Beatriz ^b   Kubera, Marta ^a   Basta Kaim, Agnieszka ^a   Budziszewska, Bogusława ^a,c   Leśkiewicz, Monika ^a   Curzytek, Katarzyna ^a   Duda, Weronika ^a   Lasoń, Władysław ^a,c   Maes, Michael ^d  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d Piyavate Hospital   (Thailand)

Author keywords

Antidepressants; B16F10 melanoma; Cytokines; Desipramine; Fluoxetine; Mirtazapine

Indexed keywords

ANTIDEPRESSANT AGENT; CONCANAVALIN A; DESIPRAMINE; FLUOXETINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; MIRTAZAPINE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG RESPONSE; GROWTH INHIBITION; IN VIVO STUDY; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; SOLID TUMOR; SPLEEN CELL; T LYMPHOCYTE; TUMOR XENOGRAFT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CELL PROLIFERATION; DESIPRAMINE; FLUOXETINE; INTERLEUKIN-10; MALE; MELANOMA, EXPERIMENTAL; MIANSERIN; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84884493175     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71045-4     Document Type: Article

References (40)

1. Abdul M, Logothetis CJ, Hoosein NM: Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol, 1995, 154, 247-250.
2. Arimochi H, Morita K: Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol, 2006, 541, 17-23. (Pubitemid 43903472)
3. Bendele RA, Adams ER, Hoffman WP, Gries CL, Morton DM: Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res, 1992, 52, 6931-6935. (Pubitemid 23006301)
4. Bilir A, Erguven M, Oktem G, Ozdemir A, Uslu A, Aktas E, Bonavida B: Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. Int J Oncol, 2008, 32, 829-839. (Pubitemid 351780593)
5. Brunda MJ, Wright RB, Luistro L, Harbison ML, Anderson TD, McIntyre KW: Enhanced antitumor efficacy in mice by combination treatment with interleukin-1 alpha and interferon-alpha. J Immunother Emphasis Tumor Immunol, 1994, 15, 233-241. (Pubitemid 24178262)
6. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW: Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl), 2002, 160, 353-361. (Pubitemid 34253277)
7. Chlebda E, Merwid-La{ogonek}d A, Szumny D, Trocha M, Fereniec- Gołe{ogonek}biewska L, Ge{ogonek}barowska E, Kowalski P, Szela{ogonek}g A: Antitumor effect of macrolides-erythromycin and roxithromycin in B16 melanoma-transplanted mice. Pharmacol Rep, 2007, 59, 269-274.
8. De Galdeano AG, Boyano D, Cańavate L: Effect induced by interleukin-1 on the behaviour of B16F10 melanoma cells. Oncol Rep, 1999, 6, 225-228.
9. Fisch M: Treatment of depression in cancer. J Natl Cancer Inst Monogr, 2004, 32, 105-111.
10. Frick LR, Palumbo ML, Zappia MP, Brocco MA, Cremaschi GA, Genaro AM: Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T-cell response by serotonin-dependent and independent mechanisms. Biochem Pharmacol, 2008, 75, 1817-1826.
11. García-Hernández ML, Hernández-Pando R, Gariglio P, Berumen J: Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology, 2002, 105, 231-243. (Pubitemid 34146690)
12. Gil-Ad I, Zolokov A, Lomnitski L, Taler M, Bar M, Luria D, Ram E, Weizman A: Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancerxenografted mice. Int J Oncol, 2008, 33, 277-286.
13. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS: Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology, 2009, 34, 2459-2468.
14. Han YS, Lee CS: Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells. Eur J Pharmacol, 2009, 604, 36-44.
15. Krishnan A, Hariharan R, Nair SA, Pillai MR: Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol, 2008, 75, 1924-1934.
16. Kubera M, Grygier B, Arteta B, Urbańska K, Basta-Kaim A, Budziszewska B, Leoekiewicz M et al.: Agedependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. Pharmacol Rep, 2009, 61, 1113-1126.
17. Kubera M, Grygier B, Urbańska K, Arteta B, Leoekiewicz M, Basta-Kaim A, Budziszewska B et al.: Inhibitory effect of fluoxetine on S91 melanoma growth in DBA mice. Cent Eur J Immun, 2008, 33, Suppl 1, 40.
18. Kubera M, Holan V, Mathison R, Maes M: The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice. Psychoneuroendocrinology, 2000, 25, 785-797. (Pubitemid 30670324)
19. Kubera M, Simbirtsev A, Mathison R, Maes M: Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res, 2000, 96, 255-266.
20. Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M, Weizman A: Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci, 2005, 27, 29-42. (Pubitemid 41112377)
21. Lieb J: Antidepressants, eicosanoids and the prevention and treatment of cancer. A review. Prostaglandins Leukot Essent Fatty Acids, 2001, 65, 233-239. (Pubitemid 34258919)
22. Lieb J: Antidepressants, prostaglandins and the prevention and treatment of cancer. A review. Med Hypotheses, 2007, 69, 684-689. (Pubitemid 47043269)
23. Lloyd-Williams M, Shiels C, Taylor F, Dennis M: Depression-an independent predictor of early death in patients with advanced cancer. J Affect Disord, 2009, 113, 127-132.
24. Luo F, Yee JK, Huang SH, Wu LT, Jong AY: Downregulation of human Cdc6 protein using a lentivirus RNA interference expression vector. Methods Mol Biol, 2006, 342, 287-293.
25. Massie MJ: Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr, 2004, 32, 57-71.
26. Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA, Ruggeri BA: Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int J Cancer, 1999, 81, 417-427. (Pubitemid 29165201)
27. Milijkovic D, Markovic M, Bogdanovic N, Mostarica Stojkovic M, Trajkovic D: Necrotic tumor cells oppositely affect nitric oxide production in tumor cell lines and macrophages. Cell Immunol, 2002, 215, 72-77.
28. Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, Ichihashi M: Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. J Invest Dermatol, 2002, 119, 541-548.
29. Ng CG, Boks MP, Zainal NZ, de Wit NJ: The prevalence and pharmacotherapy of depression in cancer patients. J Affect Disord, 2011, 131, 1-7.
30. Rodin G, Katz M, Lloyd N, Green E, Mackay JA, Wong RK: Treatment of depression in cancer patients. Curr Oncol, 2007, 14, 180-188.
31. Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, Bunce CM et al.: Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood, 2003, 101, 3212-3219. (Pubitemid 36858017)
32. Soengas MS, Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene, 2003, 22, 3138-3151. (Pubitemid 36713766)
33. Spanová A, Kovárù H, Lisá V, Lukásová E, Rittich B: Estimation of apoptosis in C6 glioma cells treated with antidepressants. Physiol Res, 1997, 46, 161-164. (Pubitemid 27263483)
34. Spiegel D: Mind matters in cancer survival. Psychooncology, 2012, 21, 588-593.
35. Steingart AB, Cotterchio M: Do antidepressants cause, promote, or inhibit cancers? A review. J Clin Epidemiol, 1995, 48, 1407-1412.
36. Stepulak A, Rzeski W, Sifringer M, Brocke K, Gratopp A, Kupisz K, Turski L, Ikonomidou C: Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther, 2008, 7, 1685-1693.
37. Sternbach H: Are antidepressants carcinogenic? A review of preclinical and clinical studies. J Clin Psychiatry, 2003, 64, 1153-1162.
38. Tutton PJ, Barkla DH: Effect of an inhibitor of noradrenaline uptake, desipramine, on cell proliferation in the intestinal crypt epithelium. Virchows Arch B Cell Pathol Incl Mol Pathol, 1989, 57, 349-352. (Pubitemid 19247119)
39. Warner-Schmidt JL, Duman RS. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA, 2007, 104, 4647-4652. (Pubitemid 47186279)
40. Zhang W, Lu Y, Xu B, Wu J, Zhang L, Gao M, Zheng S et al.: Acidic mucopolysaccharide from holothuria leucospilota has antitumor effect by inhibiting angiogenesis and tumor cell invasion in vivo and in vitro. Cancer Biol Ther, 2009, 8, 1489-1499.